Pure Global AI
NCT05975931Suspended

IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.

A Single-centre, Non-interventional, Retrospective Study to Describe the IMPACT of AspireSR® for Vagus Nerve Stimulation (VNS) Therapy on Healthcare Resource Utilisation and Clinical Outcomes.
LivaNovaClinicalTrials.gov
Verified
Study focus
Disease/Condition
Epilepsy
Study type
Observational
Sponsor & location
Primary sponsor
LivaNova
Location
Birmingham, United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Jan 20, 2022
End date
Dec 01, 2026
Enrollment
229 participants
Primary outcome

Descriptive comparison of healthcare resource use (HCRU)

Summary

This is a retrospective non-interventional study to describe the HCRU and clinical outcomes
 before and after AspireSR® device implantation in subjects with drug resistant epilepsy at
 the Queen Elizabeth Hospital, Birmingham (QEHB).

ICD-10 classifications
EpilepsyEpilepsy, unspecifiedOther epilepsyStatus epilepticusOther status epilepticus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05975931
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05975931 through Pure Global AI's free database. This phase not specified trial is sponsored by LivaNova and is currently Suspended. The study focuses on Epilepsy. Target enrollment is 229 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.